The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.
Julie Tsu-Yu WuJune CorriganChloe SuClark DumontierJennifer LaAparjita KhanShipra AryaAlex H S HarrisLeah BackhusMillie DasNhan V DoMary T BrophySummer S HanMichael KelleyNathanael R FillmorePublished in: Cancer immunology, immunotherapy : CII (2024)
Frail patients with both good and poor PS received less intensive treatment. However, frailty has a limited effect on survival among those with poor PS. These findings suggest that PS, not frailty, drives survival on intensive treatment.